GSK and Ionis report Phase 3 success for hepatitis B treatment

On September 10, 2026, GSK and Ionis Pharmaceuticals announced successful outcomes from two Phase 3 trials for their experimental hepatitis B treatment, bepirovirsen. The trials demonstrated that the drug met its primary endpoints, indicating a statistically significant functional cure rate for chronic hepatitis B. This achievement is particularly noteworthy given that over 2 billion people globally are estimated to have been infected with the hepatitis B virus, with around 300 million developing chronic infections that can lead to severe liver complications. Bepirovirsen is designed as an oligonucleotide therapy, offering the potential for a functional cure after a six-month treatment course. If successful, this treatment could enable patients to reach undetectable levels of the virus, potentially allowing them to discontinue lifelong antiviral therapies currently necessary to manage chronic hepatitis B.

The companies plan to file for global regulatory approval in the first quarter of 2026 based on the trial results, with more detailed findings expected to be published in medical journals and conferences in the future. The significance of this treatment extends beyond individual patient outcomes; it addresses a substantial public health challenge. Chronic hepatitis B infections can lead to serious health issues, including cirrhosis and liver cancer. Infants exposed to the virus are particularly vulnerable, with high rates of chronic infection among unvaccinated individuals.

The development of bepirovirsen reflects a growing demand for effective hepatitis B therapies, as evidenced by the market success of existing treatments. Analysts note that the need for effective hepatitis B treatments is rising, with competitors like Gilead’s Vemlidy achieving significant sales. The success of bepirovirsen could provide GSK with a competitive edge in the hepatitis treatment market, especially following the recent approval of a key asthma drug in its pipeline. The potential for bepirovirsen to provide a functional cure could shift treatment paradigms for chronic hepatitis B, offering a more manageable solution for patients.

As GSK and Ionis move forward with their regulatory filings, the future of bepirovirsen remains promising. With ongoing global health initiatives to combat hepatitis B, the introduction of a new, effective treatment could significantly impact public health outcomes. The collaboration between GSK and Ionis, which began in 2019, emphasizes the importance of innovation in addressing persistent health challenges and improving patient care in the realm of infectious diseases.